{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:40:16Z","timestamp":1792788016887,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Futian Healthcare Research Project","award":["FTWS2023066"],"award-info":[{"award-number":["FTWS2023066"]}]},{"name":"Shenzhen Medical Research Fund","award":["A2301047"],"award-info":[{"award-number":["A2301047"]}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2019YFA0906100"],"award-info":[{"award-number":["2019YFA0906100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2021YFC3300101"],"award-info":[{"award-number":["2021YFC3300101"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82471879"],"award-info":[{"award-number":["82471879"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2022A1515010070"],"award-info":[{"award-number":["2022A1515010070"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shenzhen Basic Science Research Project","award":["JCYJ20220531095612029"],"award-info":[{"award-number":["JCYJ20220531095612029"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-025-02548-7","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T06:45:29Z","timestamp":1764053129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["CD86 costimulation enhances the antitumor activity of NKG2D CAR-Macrophages and synergizes with Anti-PD-L1 therapy to suppress prostate cancer progression"],"prefix":"10.1186","volume":"23","author":[{"given":"Abdulrahman","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawan","family":"Rabiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengchao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Auwal","family":"Saliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoxuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guizhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"2548_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101199","volume":"4","author":"D Sridaran","year":"2023","unstructured":"Sridaran D, Bradshaw E, DeSelm C, Pachynski R, Mahajan K, Mahajan NP. Prostate cancer immunotherapy: improving clinical outcomes with a multi-pronged approach. Cell Rep Med. 2023;4:101199. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101199.","journal-title":"Cell Rep Med"},{"key":"2548_CR2","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan V, Barber-Rotenberg JS, Jung I-Y, Lacey SF, Rech AJ, Davis MM, et al. PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022;28:724\u201334. https:\/\/doi.org\/10.1038\/s41591-022-01726-1.","journal-title":"Nat Med"},{"key":"2548_CR3","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-024-02979-8","volume":"30","author":"TB Dorff","year":"2024","unstructured":"Dorff TB, Blanchard MS, Adkins LN, Luebbert L, Leggett N, Shishido SN, et al. PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2024;30:1636\u201344. https:\/\/doi.org\/10.1038\/s41591-024-02979-8.","journal-title":"Nat Med"},{"key":"2548_CR4","doi-asserted-by":"publisher","first-page":"8215","DOI":"10.1038\/s41467-025-62710-0","volume":"16","author":"K Chang","year":"2025","unstructured":"Chang K, Delavan HM, Yip E, Kasap C, Zhu J, Lodha R, et al. Modulating the PPAR\u03b3 pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer. Nat Commun. 2025;16:8215. https:\/\/doi.org\/10.1038\/s41467-025-62710-0.","journal-title":"Nat Commun"},{"key":"2548_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41556-020-00613-6","volume":"23","author":"S Chen","year":"2021","unstructured":"Chen S, Zhu G, Yang Y, Wang F, Xiao Y-T, Zhang N, et al. Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. Nat Cell Biol. 2021;23:87\u201398. https:\/\/doi.org\/10.1038\/s41556-020-00613-6.","journal-title":"Nat Cell Biol"},{"key":"2548_CR6","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41467-024-55770-1","volume":"16","author":"S Pierini","year":"2025","unstructured":"Pierini S, Gabbasov R, Oliveira-Nunes MC, Qureshi R, Worth A, Huang S, et al. Chimeric antigen receptor macrophages (CAR-M) sensitize HER2\u2009+\u2009solid tumors to PD1 blockade in pre-clinical models. Nat Commun. 2025;16:706. https:\/\/doi.org\/10.1038\/s41467-024-55770-1.","journal-title":"Nat Commun"},{"key":"2548_CR7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-018-0635-z","volume":"11","author":"Y Han","year":"2018","unstructured":"Han Y, Xie W, Song D-G, Powell DJ. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells. J Hematol Oncol. 2018;11:92. https:\/\/doi.org\/10.1186\/s13045-018-0635-z.","journal-title":"J Hematol Oncol"},{"key":"2548_CR8","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.3390\/cancers12071969","volume":"12","author":"C He","year":"2020","unstructured":"He C, Zhou Y, Li Z, Farooq MA, Ajmal I, Zhang H, et al. Co-expression of IL-7 improves NKG2D-based CAR T cell therapy on prostate cancer by enhancing the expansion and inhibiting the apoptosis and exhaustion. Cancers. 2020;12:1969. https:\/\/doi.org\/10.3390\/cancers12071969.","journal-title":"Cancers"},{"key":"2548_CR9","doi-asserted-by":"publisher","first-page":"1369406","DOI":"10.3389\/fimmu.2024.1369406","volume":"15","author":"H Zhang","year":"2024","unstructured":"Zhang H, Yao J, Ajmal I, Farooq MA, Jiang W. shRNA-mediated gene silencing of HDAC11 empowers CAR-T cells against prostate cancer. Front Immunol. 2024;15:1369406. https:\/\/doi.org\/10.3389\/fimmu.2024.1369406.","journal-title":"Front Immunol"},{"key":"2548_CR10","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1038\/s41467-025-59326-9","volume":"16","author":"S Chen","year":"2025","unstructured":"Chen S, Wang Y, Dang J, Song N, Chen X, Wang J, et al. CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation. Nat Commun. 2025;16:4069. https:\/\/doi.org\/10.1038\/s41467-025-59326-9.","journal-title":"Nat Commun"},{"key":"2548_CR11","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24:731\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0041-7.","journal-title":"Nat Med"},{"key":"2548_CR12","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24:739\u201348. https:\/\/doi.org\/10.1038\/s41591-018-0036-4.","journal-title":"Nat Med"},{"key":"2548_CR13","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s41416-019-0578-3","volume":"121","author":"W Zhang","year":"2019","unstructured":"Zhang W, Liu L, Su H, Liu Q, Shen J, Dai H, et al. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. Br J Cancer. 2019;121:837\u201345. https:\/\/doi.org\/10.1038\/s41416-019-0578-3.","journal-title":"Br J Cancer"},{"key":"2548_CR14","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38:947\u201353. https:\/\/doi.org\/10.1038\/s41587-020-0462-y.","journal-title":"Nat Biotechnol"},{"key":"2548_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.101931","volume":"6","author":"T Look","year":"2025","unstructured":"Look T, Sankowski R, Bouzereau M, Fazio S, Sun M, Buck A, et al. CAR T cells, CAR NK cells, and CAR macrophages exhibit distinct traits in glioma models but are similarly enhanced when combined with cytokines. Cell Rep Med. 2025;6:101931. https:\/\/doi.org\/10.1016\/j.xcrm.2025.101931.","journal-title":"Cell Rep Med"},{"key":"2548_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202103258","volume":"33","author":"M Kang","year":"2021","unstructured":"Kang M, Lee SH, Kwon M, Byun J, Kim D, Kim C, et al. Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy. Adv Mater. 2021;33:e2103258. https:\/\/doi.org\/10.1002\/adma.202103258.","journal-title":"Adv Mater"},{"key":"2548_CR17","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1007\/s00262-023-03490-8","volume":"72","author":"Z Duan","year":"2023","unstructured":"Duan Z, Li Z, Wang Z, Chen C, Luo Y. Chimeric antigen receptor macrophages activated through TLR4 or IFN-\u03b3 receptors suppress breast cancer growth by targeting VEGFR2. Cancer Immunol Immunother. 2023;72:3243\u201357. https:\/\/doi.org\/10.1007\/s00262-023-03490-8.","journal-title":"Cancer Immunol Immunother"},{"key":"2548_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41590-023-01687-8","volume":"25","author":"A Lei","year":"2024","unstructured":"Lei A, Yu H, Lu S, Lu H, Ding X, Tan T, et al. A second-generation M1-polarized CAR macrophage with antitumor efficacy. Nat Immunol. 2024;25:102\u201316. https:\/\/doi.org\/10.1038\/s41590-023-01687-8.","journal-title":"Nat Immunol"},{"key":"2548_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1615\/critrevimmunol.v18.i5.10","volume":"18","author":"EA Greenfield","year":"1998","unstructured":"Greenfield EA, Nguyen KA, Kuchroo VK. CD28\/B7 costimulation: a review. Crit Rev Immunol. 1998;18:389\u2013418. https:\/\/doi.org\/10.1615\/critrevimmunol.v18.i5.10.","journal-title":"Crit Rev Immunol"},{"key":"2548_CR20","doi-asserted-by":"publisher","first-page":"5362","DOI":"10.1002\/jcp.27507","volume":"234","author":"L Ni","year":"2019","unstructured":"Ni L, Zheng Y, Gong T, Xiu C, Li K, Saijilafu null, et al. Proinflammatory macrophages promote degenerative phenotypes in rat nucleus pulpous cells partly through ERK and JNK signaling. J Cell Physiol. 2019;234:5362\u201371. https:\/\/doi.org\/10.1002\/jcp.27507.","journal-title":"J Cell Physiol"},{"key":"2548_CR21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.17305\/bb.2023.9675","volume":"24","author":"K Chen","year":"2024","unstructured":"Chen K, Liu M-L, Wang J-C, Fang S. CAR-macrophage versus CAR-T for solid tumors: the race between a rising star and a superstar. Biomol Biomed. 2024;24:465\u201376. https:\/\/doi.org\/10.17305\/bb.2023.9675.","journal-title":"Biomol Biomed"},{"issue":"25","key":"2548_CR22","doi-asserted-by":"publisher","first-page":"00004","DOI":"10.1016\/j.jare.2025.01.004","volume":"S2090\u20131232","author":"Y Chen","year":"2025","unstructured":"Chen Y, Xin Q, Zhu M, Qiu J, Luo Y, Li R, et al. Exploring CAR-macrophages in non-tumor diseases: therapeutic potential beyond cancer. J Adv Res. 2025;S2090\u20131232(25):00004\u20139. https:\/\/doi.org\/10.1016\/j.jare.2025.01.004.","journal-title":"J Adv Res"},{"key":"2548_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0642-9","volume":"7","author":"D Yang","year":"2019","unstructured":"Yang D, Sun B, Dai H, Li W, Shi L, Zhang P, et al. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells. J Immunother Cancer. 2019;7:171. https:\/\/doi.org\/10.1186\/s40425-019-0642-9.","journal-title":"J Immunother Cancer"},{"key":"2548_CR24","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20182005","volume":"217","author":"D Yan","year":"2020","unstructured":"Yan D, Wang J, Sun H, Zamani A, Zhang H, Chen W, et al. TIPE2 specifies the functional polarization of myeloid-derived suppressor cells during tumorigenesis. J Exp Med. 2020;217:e20182005. https:\/\/doi.org\/10.1084\/jem.20182005.","journal-title":"J Exp Med"},{"key":"2548_CR25","doi-asserted-by":"publisher","first-page":"4819","DOI":"10.7150\/jca.58670","volume":"12","author":"FO Adeshakin","year":"2021","unstructured":"Adeshakin FO, Adeshakin AO, Liu Z, Lu X, Cheng J, Zhang P, et al. Upregulation of V-ATPase by STAT3 activation promotes anoikis resistance and tumor metastasis. J Cancer. 2021;12:4819\u201329. https:\/\/doi.org\/10.7150\/jca.58670.","journal-title":"J Cancer"},{"key":"2548_CR26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12967-023-04061-2","volume":"21","author":"Y Huo","year":"2023","unstructured":"Huo Y, Zhang H, Sa L, Zheng W, He Y, Lyu H, et al. M1 polarization enhances the antitumor activity of chimeric antigen receptor macrophages in solid tumors. J Transl Med. 2023;21:225. https:\/\/doi.org\/10.1186\/s12967-023-04061-2.","journal-title":"J Transl Med"},{"key":"2548_CR27","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41416-023-02319-6","volume":"129","author":"X Dong","year":"2023","unstructured":"Dong X, Fan J, Xie W, Wu X, Wei J, He Z, et al. Efficacy evaluation of chimeric antigen receptor-modified human peritoneal macrophages in the treatment of gastric cancer. Br J Cancer. 2023;129:551\u201362. https:\/\/doi.org\/10.1038\/s41416-023-02319-6.","journal-title":"Br J Cancer"},{"key":"2548_CR28","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jhep.2024.01.034","volume":"80","author":"H Dai","year":"2024","unstructured":"Dai H, Zhu C, Huai Q, Xu W, Zhu J, Zhang X, et al. Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models. J Hepatol. 2024;80:913\u201327. https:\/\/doi.org\/10.1016\/j.jhep.2024.01.034.","journal-title":"J Hepatol"},{"key":"2548_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61560-0","author":"W Li","year":"2025","unstructured":"Li W, Chen S, Lu J, Mao W, Zheng S, Zhang M, et al. YY1 enhances HIF-1\u03b1 stability in tumor-associated macrophages to suppress anti-tumor immunity of prostate cancer in mice. Nat Commun. 2025. https:\/\/doi.org\/10.1038\/s41467-025-61560-0.","journal-title":"Nat Commun"},{"key":"2548_CR30","doi-asserted-by":"publisher","first-page":"6913","DOI":"10.7150\/thno.100555","volume":"14","author":"SB Hansen","year":"2024","unstructured":"Hansen SB, Unal B, Kuzu OF, Saatcioglu F. Immunological facets of prostate cancer and the potential of immune checkpoint inhibition in disease management. Theranostics. 2024;14:6913\u201334. https:\/\/doi.org\/10.7150\/thno.100555.","journal-title":"Theranostics"},{"key":"2548_CR31","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41417-025-00886-9","volume":"32","author":"A Ibrahim","year":"2025","unstructured":"Ibrahim A, Mohamady Farouk Abdalsalam N, Liang Z, Kashaf Tariq H, Li R, O Afolabi L, et al. MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy. Cancer Gene Ther. 2025;32:371\u201392. https:\/\/doi.org\/10.1038\/s41417-025-00886-9.","journal-title":"Cancer Gene Ther"},{"key":"2548_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13045-020-00983-2","volume":"13","author":"L Zhang","year":"2020","unstructured":"Zhang L, Tian L, Dai X, Yu H, Wang J, Lei A, et al. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. J Hematol Oncol. 2020;13:153. https:\/\/doi.org\/10.1186\/s13045-020-00983-2.","journal-title":"J Hematol Oncol"},{"key":"2548_CR33","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/s41419-024-07267-4","volume":"15","author":"L Ziane-Chaouche","year":"2024","unstructured":"Ziane-Chaouche L, Raffo-Romero A, Hajjaji N, Kobeissy F, Pinheiro D, Aboulouard S, et al. Inhibition of Furin in CAR macrophages directs them toward a proinflammatory phenotype and enhances their antitumor activities. Cell Death Dis. 2024;15:879. https:\/\/doi.org\/10.1038\/s41419-024-07267-4.","journal-title":"Cell Death Dis"},{"key":"2548_CR34","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1186\/s12967-023-04479-8","volume":"21","author":"Y Chen","year":"2023","unstructured":"Chen Y, Zhu X, Liu H, Wang C, Chen Y, Wang H, et al. The application of HER2 and CD47 CAR-macrophage in ovarian cancer. J Transl Med. 2023;21:654. https:\/\/doi.org\/10.1186\/s12967-023-04479-8.","journal-title":"J Transl Med"},{"key":"2548_CR35","doi-asserted-by":"publisher","first-page":"121137","DOI":"10.1016\/j.biomaterials.2021.121137","volume":"278","author":"GR Gunassekaran","year":"2021","unstructured":"Gunassekaran GR, Poongkavithai Vadevoo SM, Baek M-C, Lee B. M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials. 2021;278:121137. https:\/\/doi.org\/10.1016\/j.biomaterials.2021.121137.","journal-title":"Biomaterials"},{"key":"2548_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltab018","volume":"1","author":"S Curio","year":"2021","unstructured":"Curio S, Jonsson G, Marinovi\u0107 S. A summary of current NKG2D-based CAR clinical trials. Immunother Adv. 2021;1:ltab018. https:\/\/doi.org\/10.1093\/immadv\/ltab018.","journal-title":"Immunother Adv"},{"key":"2548_CR37","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/9988405","volume":"2023","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Ma R, Chen H, Guo W, Li Z, Xu K, et al. CD86 is associated with immune infiltration and immunotherapy signatures in AML and promotes its progression. J Oncol. 2023;2023:9988405. https:\/\/doi.org\/10.1155\/2023\/9988405.","journal-title":"J Oncol"},{"key":"2548_CR38","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.3390\/cells11223692","volume":"11","author":"M Liu","year":"2022","unstructured":"Liu M, Liu J, Liang Z, Dai K, Gan J, Wang Q, et al. CAR-macrophages and CAR-T cells synergistically kill tumor cells in vitro. Cells. 2022;11:3692. https:\/\/doi.org\/10.3390\/cells11223692.","journal-title":"Cells"},{"key":"2548_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2024.105353","volume":"26","author":"U Barrie","year":"2024","unstructured":"Barrie U, Floyd K, Datta A, Wetzel DM. MAPK\/ERK activation in macrophages promotes Leishmania internalization and pathogenesis. Microbes Infect. 2024;26:105353. https:\/\/doi.org\/10.1016\/j.micinf.2024.105353.","journal-title":"Microbes Infect"},{"key":"2548_CR40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12951-022-01273-4","volume":"20","author":"C Liu","year":"2022","unstructured":"Liu C, Hu F, Jiao G, Guo Y, Zhou P, Zhang Y, et al. Dental pulp stem cell-derived exosomes suppress M1 macrophage polarization through the ROS-MAPK-NF\u03baB P65 signaling pathway after spinal cord injury. J Nanobiotechnol. 2022;20:65. https:\/\/doi.org\/10.1186\/s12951-022-01273-4.","journal-title":"J Nanobiotechnol"},{"key":"2548_CR41","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s42003-022-03369-x","volume":"5","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Takano T, Li X, Wang Y, Wang R, Zhu Z, et al. \u03b2-elemene regulates M1-M2 macrophage balance through the ERK\/JNK\/P38 MAPK signaling pathway. Commun Biol. 2022;5:519. https:\/\/doi.org\/10.1038\/s42003-022-03369-x.","journal-title":"Commun Biol"},{"key":"2548_CR42","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41591-022-01765-8","volume":"28","author":"AV Finck","year":"2022","unstructured":"Finck AV, Blanchard T, Roselle CP, Golinelli G, June CH. Engineered cellular immunotherapies in cancer and beyond. Nat Med. 2022;28:678\u201389. https:\/\/doi.org\/10.1038\/s41591-022-01765-8.","journal-title":"Nat Med"},{"key":"2548_CR43","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545:495\u20139. https:\/\/doi.org\/10.1038\/nature22396.","journal-title":"Nature"},{"key":"2548_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02124-y","volume":"10","author":"F Guan","year":"2025","unstructured":"Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y, et al. Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets. Signal Transduct Target Ther. 2025;10:93. https:\/\/doi.org\/10.1038\/s41392-025-02124-y.","journal-title":"Signal Transduct Target Ther"},{"key":"2548_CR45","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.stem.2024.03.018","volume":"31","author":"Z Shah","year":"2024","unstructured":"Shah Z, Tian L, Li Z, Jin L, Zhang J, Li Z, et al. Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer. Cell Stem Cell. 2024;31:803-817.e6. https:\/\/doi.org\/10.1016\/j.stem.2024.03.018.","journal-title":"Cell Stem Cell"},{"key":"2548_CR46","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1158\/0008-5472.CAN-05-2520","volume":"66","author":"I Waldhauer","year":"2006","unstructured":"Waldhauer I, Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res. 2006;66:2520\u20136. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-2520.","journal-title":"Cancer Res"},{"key":"2548_CR47","doi-asserted-by":"publisher","first-page":"9452","DOI":"10.1073\/pnas.1632807100","volume":"100","author":"V Groh","year":"2003","unstructured":"Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2003;100:9452\u20137. https:\/\/doi.org\/10.1073\/pnas.1632807100.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2548_CR48","doi-asserted-by":"publisher","first-page":"5778","DOI":"10.1038\/s41467-023-41470-9","volume":"14","author":"X Wang","year":"2023","unstructured":"Wang X, Su S, Zhu Y, Cheng X, Cheng C, Chen L, et al. Metabolic reprogramming via ACOD1 depletion enhances function of human induced pluripotent stem cell-derived CAR-macrophages in solid tumors. Nat Commun. 2023;14:5778. https:\/\/doi.org\/10.1038\/s41467-023-41470-9.","journal-title":"Nat Commun"},{"key":"2548_CR49","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jconrel.2023.07.021","volume":"360","author":"Z Yang","year":"2023","unstructured":"Yang Z, Liu Y, Zhao K, Jing W, Gao L, Dong X, et al. Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy. J Control Release. 2023;360:718\u201333. https:\/\/doi.org\/10.1016\/j.jconrel.2023.07.021.","journal-title":"J Control Release"},{"key":"2548_CR50","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.bioactmat.2024.04.004","volume":"38","author":"Q Guo","year":"2024","unstructured":"Guo Q, Qian Z-M. Macrophage based drug delivery: key challenges and strategies. Bioact Mater. 2024;38:55\u201372. https:\/\/doi.org\/10.1016\/j.bioactmat.2024.04.004.","journal-title":"Bioact Mater"},{"key":"2548_CR51","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41467-023-37872-4","volume":"14","author":"Y Chang","year":"2023","unstructured":"Chang Y, Cai X, Syahirah R, Yao Y, Xu Y, Jin G, et al. CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy. Nat Commun. 2023;14:2266. https:\/\/doi.org\/10.1038\/s41467-023-37872-4.","journal-title":"Nat Commun"},{"key":"2548_CR52","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40364-024-00637-2","volume":"12","author":"J Lu","year":"2024","unstructured":"Lu J, Ma Y, Li Q, Xu Y, Xue Y, Xu S. CAR macrophages: a promising novel immunotherapy for solid tumors and beyond. Biomark Res. 2024;12:86. https:\/\/doi.org\/10.1186\/s40364-024-00637-2.","journal-title":"Biomark Res"},{"key":"2548_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-025-01387-8","author":"Q Cao","year":"2025","unstructured":"Cao Q, Wang Y, Chen J, Wang R, Chen T, Gloss B, et al. Targeting inflammation with chimeric antigen receptor macrophages using a signal switch. Nat Biomed Eng. 2025. https:\/\/doi.org\/10.1038\/s41551-025-01387-8.","journal-title":"Nat Biomed Eng"},{"key":"2548_CR54","doi-asserted-by":"publisher","first-page":"1291619","DOI":"10.3389\/fimmu.2023.1291619","volume":"14","author":"Y Liang","year":"2023","unstructured":"Liang Y, Xu Q, Gao Q. Advancing CAR-based immunotherapies in solid tumors: CAR- macrophages and neutrophils. Front Immunol. 2023;14:1291619. https:\/\/doi.org\/10.3389\/fimmu.2023.1291619.","journal-title":"Front Immunol"},{"key":"2548_CR55","doi-asserted-by":"publisher","first-page":"1385571","DOI":"10.3389\/fimmu.2024.1385571","volume":"15","author":"Z Niu","year":"2024","unstructured":"Niu Z, Wu J, Zhao Q, Zhang J, Zhang P, Yang Y. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies. Front Immunol. 2024;15:1385571. https:\/\/doi.org\/10.3389\/fimmu.2024.1385571.","journal-title":"Front Immunol"},{"key":"2548_CR56","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cytogfr.2025.09.004","volume":"86","author":"S Upadhyay","year":"2025","unstructured":"Upadhyay S, Upmanyu K, Gabr MT. Designing immunity with cytokines: a logic-based framework for programmable CAR therapies. Cytokine Growth Factor Rev. 2025;86:40\u201355. https:\/\/doi.org\/10.1016\/j.cytogfr.2025.09.004.","journal-title":"Cytokine Growth Factor Rev"},{"key":"2548_CR57","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1158\/1078-0432.CCR-25-1201","volume":"31","author":"D Wei","year":"2025","unstructured":"Wei D, Wang L, Liu Y, Zuo X, Shen X, Bresalier RS. CAR-macrophage cell therapy: a new era of hope for pancreatic cancer. Clin Cancer Res. 2025;31:4018\u201331. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-1201.","journal-title":"Clin Cancer Res"},{"key":"2548_CR58","doi-asserted-by":"publisher","first-page":"783305","DOI":"10.3389\/fimmu.2021.783305","volume":"12","author":"C Sloas","year":"2021","unstructured":"Sloas C, Gill S, Klichinsky M. Engineered CAR-macrophages as adoptive immunotherapies for solid tumors. Front Immunol. 2021;12:783305. https:\/\/doi.org\/10.3389\/fimmu.2021.783305.","journal-title":"Front Immunol"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02548-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02548-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02548-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:35:34Z","timestamp":1767054934000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-025-02548-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2548"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02548-7","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The research was approved by the Institutional Animal Care and Use Committee of the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"548"}}